review article | Q7318358 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1020038270 |
P356 | DOI | 10.1186/AR2171 |
P8608 | Fatcat ID | release_63abqnt2ovdztjcw6bbsngruyu |
P932 | PMC publication ID | 1924522 |
P698 | PubMed publication ID | 17634146 |
P5875 | ResearchGate publication ID | 6204547 |
P50 | author | Christopher T Ritchlin | Q80623665 |
P2093 | author name string | Edward M Schwarz | |
P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
RANK is essential for osteoclast and lymph node development | Q24598872 | ||
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis | Q28216662 | ||
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws | Q28240354 | ||
Denosumab in postmenopausal women with low bone mineral density | Q28298728 | ||
The long and the short of bone therapy | Q28298737 | ||
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
Osteoclast differentiation and activation | Q29547556 | ||
Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis | Q33561675 | ||
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies | Q33825182 | ||
Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role | Q35605709 | ||
Human antibodies from transgenic animals | Q36252986 | ||
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength | Q36269835 | ||
Fully human therapeutic monoclonal antibodies | Q36347397 | ||
TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation | Q36368029 | ||
Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions | Q41355139 | ||
The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 | ||
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 | ||
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease | Q44334690 | ||
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis | Q44590934 | ||
Regulatory effects of osteoprotegerin on cellular and humoral immune responses | Q44707640 | ||
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats | Q46099755 | ||
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. | Q46281657 | ||
Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. | Q46687366 | ||
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 | ||
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing | Q47846447 | ||
RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. | Q51032592 | ||
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. | Q51797992 | ||
Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial | Q71016803 | ||
Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis | Q72201830 | ||
Osteonecrosis of the jaw: more research needed | Q80331532 | ||
P921 | main subject | peptide | Q172847 |
pharmaceutical science | Q7180763 | ||
biomedical investigative technique | Q66648976 | ||
P304 | page(s) | S7 | |
P577 | publication date | 2007-01-01 | |
P1433 | published in | Arthritis Research and Therapy | Q15757229 |
P1476 | title | Clinical development of anti-RANKL therapy | |
P478 | volume | 9 Suppl 1 |
Q42659386 | A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy |
Q38175846 | A multi-targeted approach to treating bone metastases. |
Q82871104 | A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease |
Q39751683 | Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models |
Q37821350 | Androgen deprivation and bone |
Q37354121 | Aromatase inhibitor-associated bone loss: clinical considerations |
Q34111621 | Bone Health in Nonmetastatic Prostate Cancer: What’s the Big Deal? |
Q92152784 | Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders |
Q33754036 | Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options |
Q40231039 | Calreticulin inhibits inflammation-induced osteoclastogenesis and bone resorption |
Q43205303 | Cancer pain physiology |
Q51730575 | Cell-based glycan arrays for probing glycan-glycan binding protein interactions. |
Q37029680 | Cervical actinomycosis with spinal cord compression. Case report and literature review |
Q35003674 | Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies |
Q34960778 | Contemporary therapeutic approaches targeting bone complications in prostate cancer |
Q36890431 | Current and emerging therapies for the treatment of osteoporosis |
Q37152851 | Current state and future of joint replacements in the hip and knee |
Q37342578 | Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. |
Q35622970 | Effect of bisphosphonates on orthodontic tooth movement-an update |
Q34162783 | Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw. |
Q37658767 | Emerging therapeutic targets in breast cancer bone metastasis |
Q37230477 | Emerging treatments for postmenopausal osteoporosis - focus on denosumab |
Q35844745 | Glucocorticoid use in acute lymphoblastic leukaemia |
Q34482369 | High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation |
Q38944092 | Hormonal Modulation of Dendritic Cells Differentiation, Maturation and Function: Implications for the Initiation and Progress of Systemic Autoimmunity. |
Q34991655 | Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim. |
Q36952052 | Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients |
Q81344046 | Is denosumab a safe and effective treatment for postmenopausal osteoporosis? |
Q33862655 | Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model |
Q35310572 | Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis |
Q36823728 | Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow |
Q33953955 | Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. |
Q38616755 | New management options for osteoporosis with emphasis on SERMs |
Q38209656 | Novel agents in the management of castration resistant prostate cancer. |
Q37720488 | Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. |
Q33642278 | Novel targeted therapeutics for metastatic castration-resistant prostate cancer. |
Q38845640 | Osteocytic signalling pathways as therapeutic targets for bone fragility |
Q38206487 | Osteoprotegerin and kidney disease |
Q37011060 | Painful boney metastases |
Q37187646 | Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. |
Q39170948 | Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss |
Q33757791 | Prostate cancer and bone: the elective affinities. |
Q27009529 | Review of periprosthetic osteolysis in total joint arthroplasty: an emphasis on host factors and future directions |
Q37571986 | Role of denosumab in breast cancer |
Q33900327 | Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence |
Q34634763 | Targeted therapy in prostate cancer |
Q27687098 | Targeting dendritic cell function during systemic autoimmunity to restore tolerance |
Q34108110 | The emerging field of osteoimmunology |
Q37825905 | Therapeutic targeting of osteoclast function and pathways. |
Q34441944 | Treatment and prevention of bone complications from prostate cancer |
Q82908399 | [Physiopathology, diagnosis and management of bone metastases from prostate cancer] |